Cimlanod

Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitroxyl donor.[1]

Cimlanod
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • N-Hydroxy-5-methylfuran-2-sulfonamide
CAS Number
PubChem CID
DrugBank
UNII
Chemical and physical data
FormulaC5H7NO4S
Molar mass177.17 g·mol−1
3D model (JSmol)
SMILES
  • CC1=CC=C(O1)S(=O)(=O)NO

Cimlanod is a prodrug of CXL-1020.[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]

References
  1. "BMS 986231". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22. Alternative Names: BMS-986231; CXL 1427; HNO Donor
  2. "CXL 1020". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.
  3. Zoler ML (22 May 2016). "Nitroxl prodrug shows promise in acute heart failure".
  4. Clinical trial number NCT02157506 for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" at ClinicalTrials.gov
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.